Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study
- PMID: 10801172
- DOI: 10.1016/S0140-6736(00)02165-6
Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study
Abstract
Background: The best treatment (steroids, irradiation, or both) for moderately severe Graves' orbitopathy, a self-limiting disease is not known. We tested the efficacy of external beam irradiation compared with sham-irradiation.
Methods: In a double-blind randomised clinical trial, 30 patients with moderately severe Graves' orbitopathy had radiotherapy (20 Gy in ten fractions), and 30 were assigned sham-irradiation (ten fractions of 0 Gy). Treatment outcome was measured qualitatively by changes in major and minor criteria and quantitatively in several ophthalmic and other variables, such as eyelid aperture, proptosis, eye movements, subjective eye score, and clinical-activity score at 24 weeks.
Findings: The qualitative treatment outcome was successful in 18 of 30 (60%) irradiated patients versus nine of 29 (31%) sham-irradiated patients at week 24 (relative risk [RR]=1.9 [95% CI 1.0-3.6], p=0.04). This difference was caused by improvements in diplopia grade, but not by reduction of proptosis, nor of eyelid swelling. Quantitatively, elevation improved significantly in the radiotherapy group, whereas all other variables remained unchanged. The field of binocular single vision was enlarged in 11 of 17 patients after irradiation compared with two of 15 after sham-irradiation. Nevertheless, only 25% of the irradiated patients were spared from additional strabismus surgery.
Interpretation: In these patients with moderately severe Graves' orbitopathy, radiotherapy should be used only to treat motility impairment.
Similar articles
-
A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy.J Clin Endocrinol Metab. 2004 Jan;89(1):15-20. doi: 10.1210/jc.2003-030809. J Clin Endocrinol Metab. 2004. PMID: 14715820 Clinical Trial.
-
A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy.Graefes Arch Clin Exp Ophthalmol. 2010 Jan;248(1):103-9. doi: 10.1007/s00417-009-1214-3. Epub 2009 Oct 29. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 19865824
-
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31. Lancet Diabetes Endocrinol. 2018. PMID: 29396246 Clinical Trial.
-
[Radiotherapy for Graves' ophthalmopathy].Klin Monbl Augenheilkd. 2004 Nov;221(11):915-21. doi: 10.1055/s-2004-813774. Klin Monbl Augenheilkd. 2004. PMID: 15562354 Review. German.
-
Optimal management of Graves orbitopathy: a multidisciplinary approach.Neth J Med. 2011 Jul-Aug;69(7):302-8. Neth J Med. 2011. PMID: 21934174 Review.
Cited by
-
Low- vs. high-dose radiotherapy in Graves' ophthalmopathy: a retrospective comparison of long-term results.Strahlenther Onkol. 2021 Oct;197(10):885-894. doi: 10.1007/s00066-021-01770-9. Epub 2021 Apr 16. Strahlenther Onkol. 2021. PMID: 33860819 Free PMC article.
-
[Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].Ophthalmologe. 2003 Oct;100(10):857-80. doi: 10.1007/s00347-003-0873-4. Ophthalmologe. 2003. PMID: 14986660 Review. German. No abstract available.
-
Graves' orbitopathy: imperfect treatments for a rare disease.Eur Thyroid J. 2013 Dec;2(4):259-69. doi: 10.1159/000356042. Epub 2013 Nov 20. Eur Thyroid J. 2013. PMID: 24783057 Free PMC article. Review.
-
Longer treatment time and lower radiation doses-an alternative for Graves' ophthalmopathy treatment.Strahlenther Onkol. 2022 Jul;198(7):663-664. doi: 10.1007/s00066-021-01852-8. Epub 2021 Oct 1. Strahlenther Onkol. 2022. PMID: 34596698 No abstract available.
-
Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy.Korean J Ophthalmol. 2012 Apr;26(2):73-9. doi: 10.3341/kjo.2012.26.2.73. Epub 2012 Mar 22. Korean J Ophthalmol. 2012. PMID: 22511831 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources